Wire · opportunities
FDA-approved ketamine treatment fights depression better than decades on Prozac, patients say
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 15 October 2026 · Fusion42 review
Mather Hospital in New York is using FDA-approved esketamine nasal spray to treat patients with severe depression, with 62% reporting symptom improvement. The treatment targets different pathways than traditional antidepressants and is managed with strict safety protocols.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
You have a new, FDA-approved tool radically different from conventional antidepressants to improve outcomes in treatment-resistant depression. Early adoption could help your mental health platform stand out by offering faster, more effective therapies.
◆ Coverage
1 source · 15 Oct 2026
◆ Related on Wire
◆ Topics